Direct-to-consumer genome testing: opportunities for pharmacogenomics research? | Zendy

Barbara Prainsack | Zendy; Howard Wolinsky | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

Author(s) -

Barbara Prainsack,

Howard Wolinsky

Publication year - 2010

Publication title -

pharmacogenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.541

H-Index - 91

eISSN - 1744-8042

pISSN - 1462-2416

DOI - 10.2217/pgs.10.33

Subject(s) - pharmacogenomics , crowdsourcing , personal genomics , genome , personalized medicine , genomics , data science , snp , computational biology , internet privacy , medicine , computer science , bioinformatics , genetics , world wide web , biology , pharmacology , gene , single nucleotide polymorphism , genotype

This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of ‘crowdsourcing’ pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research